Evaluation of Progression-Free Survival (PFS) As a Surrogate Endpoint for Overall Survival (OS) in First-Line Therapy for Diffuse Large B-Cell Lymphoma (DLBCL): Findings from the Surrogate Endpoint in Aggressive Lymphoma (SEAL) Analysis of Individual Patient Data from 7507 Patients
Year: 2016
Type: article
Source: Blood
Authors: Qian Shi, Norbert Schmitz, Christopher Flowers, Fang-Shu Ou, David Cunningham, Michael Pfreundschuh, John F Seymour, Ulrich Jaeger, Thomas M. Habermann, Corinne Haioun, Hervé Tilly, Herve Ghesquieres, Francesco Merli, Marita Ziepert, Raoul Herbrecht, Jocelyne Flament, Tommy Fu, Bertrand Coiffier, Daniel Sargent
Institutions: Mayo Clinic, Asklepios Klinik St. Georg, Asklepios, Emory University, Winship Cancer Institute, Royal Marsden Hospital, Saarland University, Peter MacCallum Cancer Centre, Medical University of Vienna, Centre Hospitalier Universitaire Henri-Mondor, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Henri-Mondor, Centre Henri Becquerel, Université de Rouen Normandie, Hôpital Lyon Sud, Santa Maria Nuova Hospital, Leipzig University, Hôpital d'Hautepierre, Celgene (Switzerland), Celgene (United States)
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2596887384